Cognitive adaptations for memory deficits in MCI and AD patients: A meta-analysis of EEG microstates

Timothy Piton1, Una Smailovic2, Vesna Jelic3

  • 1Department of Fundamental Neurosciences, University of Geneva, Switzerland.

Neuroimage. Clinical
|January 7, 2026
PubMed
Abstract

Insights

Alzheimer's disease (AD) and mild cognitive impairment (MCI) patients show altered brain activity patterns. EEG microstate analysis reveals disruptions in cognitive control and memory, with potential compensation through verbalization and visualization.

Area of Science:

  • Neuroscience
  • Cognitive Science

Background:

  • Electroencephalography (EEG) microstate analysis reveals brain network dynamics during distinct mental states.
  • Alterations in microstates are implicated in neurodegenerative conditions like Alzheimer's disease (AD) and mild cognitive impairment (MCI).
  • Previous research shows conflicting results regarding microstate A (auditory/language) and microstate C (self-related memory, mind-wandering) in AD and MCI.

Purpose of the Study:

  • To systematically investigate alterations in the four canonical EEG microstates (A, B, C, and D) in MCI and AD patients compared to healthy older adults.
  • To clarify the specific temporal parameter changes (mean duration, occurrence rate, time coverage) associated with each microstate in these populations.

Main Methods:

  • A meta-analysis was conducted comparing microstate temporal parameters.
  • Included 12 studies with 1347 participants (448 MCI, 514 AD, 385 controls).
  • Analyzed resting-state, eyes-closed EEG data.

Main Results:

  • AD patients exhibited increased duration and time coverage of microstate A, and increased duration of microstate B.
  • AD patients showed reduced occurrence of microstates C and D.
  • MCI patients displayed increased duration, occurrence, and time coverage of microstate A, and reduced parameters for microstate D.

Conclusions:

  • MCI and AD patients demonstrate disrupted cognitive control, memory, and self-referential processing.
  • These deficits may be compensated by increased verbalization and visualization to maintain cognitive engagement.
  • EEG microstate alterations provide insights into the neural underpinnings of cognitive decline in AD and MCI.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
544
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
768
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806